Merck & Co. (MRK) Announces FDA Approval of KEYTRUDA® and KEYTRUDA QLEX™ Plus Paclitaxel, With or Without Bevacizumab, to Treat Adults With PD-L1+

by | Feb 13, 2026 | Uncategorized

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments